Key Points
- Director Phillip Md Et Al Frost bought 20,000 shares of Cocrystal Pharma on Dec. 30 at $0.97, bringing his direct holdings to 1,788,551 shares; he purchased roughly 109,000 shares total in late November–December at about $0.94–$0.99 per share.
- Cocrystal Pharma trades near $0.98 with a market capitalization of roughly $13.49 million, a 12‑month range of $0.90–$2.67, and 50‑/200‑day simple moving averages of $1.03 and $1.32.
- Analyst coverage is limited and mixed — one Buy and one Sell produce a consensus "Hold" and a $6.00 target, Weiss Ratings reaffirmed a "sell (e+)," and the company reported -$0.19 EPS last quarter, slightly beating estimates.
Cocrystal Pharma, Inc. (NASDAQ:COCP - Get Free Report) Director Phillip Md Et Al Frost acquired 20,000 shares of the company's stock in a transaction dated Tuesday, December 30th. The stock was purchased at an average cost of $0.97 per share, for a total transaction of $19,400.00. Following the purchase, the director directly owned 1,788,551 shares in the company, valued at approximately $1,734,894.47. This represents a 1.13% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through this link.
Phillip Md Et Al Frost also recently made the following trade(s):
- On Friday, December 26th, Phillip Md Et Al Frost bought 40,000 shares of Cocrystal Pharma stock. The shares were purchased at an average cost of $0.97 per share, with a total value of $38,800.00.
- On Wednesday, December 24th, Phillip Md Et Al Frost purchased 25,000 shares of Cocrystal Pharma stock. The stock was acquired at an average price of $0.97 per share, for a total transaction of $24,250.00.
- On Wednesday, November 26th, Phillip Md Et Al Frost acquired 4,000 shares of Cocrystal Pharma stock. The shares were acquired at an average price of $0.99 per share, with a total value of $3,960.00.
- On Tuesday, November 25th, Phillip Md Et Al Frost acquired 20,000 shares of Cocrystal Pharma stock. The stock was acquired at an average cost of $0.94 per share, for a total transaction of $18,800.00.
Cocrystal Pharma Price Performance
NASDAQ COCP opened at $0.98 on Thursday. The company's 50 day simple moving average is $1.03 and its 200 day simple moving average is $1.32. Cocrystal Pharma, Inc. has a 12 month low of $0.90 and a 12 month high of $2.67. The company has a market capitalization of $13.49 million, a P/E ratio of -1.04 and a beta of 1.05.
Cocrystal Pharma (NASDAQ:COCP - Get Free Report) last issued its earnings results on Friday, November 14th. The company reported ($0.19) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.03. On average, analysts anticipate that Cocrystal Pharma, Inc. will post -1.85 earnings per share for the current year.
Analysts Set New Price Targets
Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Cocrystal Pharma in a report on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $6.00.
Check Out Our Latest Report on Cocrystal Pharma
About Cocrystal Pharma
(
Get Free Report)
Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.
The company's pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
